New activity is brewing for Centessa Pharmaceuticals ( (CNTA) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Centessa Pharmaceuticals has called special shareholder meetings on June 12, 2026 in London to vote on a proposed acquisition by Eli Lilly, to be implemented via a court-sanctioned scheme of arrangement under U.K. company law. Ordinary shareholders and ADS holders are being asked to approve the scheme and a related special resolution authorizing board actions and amendments to the company’s articles to enable the deal.
Under the terms of the transaction, Centessa investors would receive $38.00 in cash per ordinary share or ADS plus a non-transferable contingent value right worth up to an additional $9.00 per share or ADS if specified milestones are met. The board, acting on legal and financial advice, has unanimously endorsed the deal as being in the best interests of shareholders, and completion would see Centessa become a Lilly subsidiary, ending its independent listing and crystallizing value for holders subject to the outcome of the votes and court approval.
The most recent analyst rating on (CNTA) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Neutral.
The score is driven by the announced Lilly acquisition (supportive near-term value anchor) and strong technical momentum, partially offset by weak operating performance with ongoing losses and cash burn, and limited traditional valuation support due to negative earnings.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals is a U.K.-incorporated biopharmaceutical company focused on developing clinical-stage drug candidates, including sleep and orexin-related therapies such as cleminorexton (formerly ORX750), ORX142 and ORX489. Its shares trade both as ordinary shares in the U.K. register and as American Depositary Shares on Nasdaq, giving it exposure to global healthcare and life sciences investors.
Average Trading Volume: 2,617,039
Technical Sentiment Signal: Buy
Current Market Cap: $5.91B
For detailed information about CNTA stock, go to TipRanks’ Stock Analysis page.